Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade

Phase 3, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Merck & Co. Primary endpoints: Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium up to 3 hours and Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium up to 6 hours. Started Nov 2005; status: completed.